Cardiac myxomas: A narrative review

A K M Monwarul Islam

A K M Monwarul Islam, Department of Cardiology, National Institute of Cardiovascular Diseases, Dhaka 1207, Bangladesh

Corresponding author: A K M Monwarul Islam, MD, FCPS, FACC, FESC, FASE, FACP, FRCP, Associate Professor, Department of Cardiology, National Institute of Cardiovascular Diseases, Sher-e-Bangla Nagar, Dhaka 1207, Bangladesh. drmonwarbd@yahoo.com

Abstract

Cardiac myxomas are common primary neoplasms of the heart. They are biologically benign but “functionally malignant” because of the potential for embolization. They arise most commonly from the left atrium, but no chambers of the heart are immune. They may be sporadic in the majority but also familial as a part of the Carney complex. Two morphological forms exist: polypoid and papillary. Polypoid myxomas often present with obstructive features, while the papillary forms are more prone to embolization. Histogenesis is still controversial; the current view centres around origin from the primitive pluripotent mesenchymal cells. They may be of giant proportion, be calcified or get infected. Clinical presentation typically involves the triad of intracardiac obstruction, embolic events and constitutional symptoms. Precordial examination findings may simulate those of mitral or tricuspid stenosis. The presence of tumour plop and change of the physical findings with changing position may help differentiation between the two. Echocardiography is the investigation of choice. Echogenic polypoid or papillary mobile mass within the atrial cavity remaining attached to the interatrial septum through a stalk are the tell-tale echocardiographic features. Cardiac magnetic resonance and computed tomographic scanning may have incremental diagnostic value. Histopathological examination reveals abundant loose myxoid stroma with scattered round, polygonal or stellate cells with dense irregular nuclei. Genetic testing may detect mutations in the PRKAR1A gene in the familial form of cardiac myxoma, i.e. the Carney complex. Surgical excision is the mainstay of treatment with low operative mortality, excellent postoperative survival and low recurrence rate. The current trend favours minimal-access surgery with or without robotic assistance. Physicians should have appropriate preparedness to make a timely diagnosis and enthusiastic treatment to avoid potentially fatal complications.

Key Words: Myxoma; Cardiac; Neoplasm; Carney Complex; Echocardiography; Embolism

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Cardiac myxomas are biologically benign but “functionally malignant”. They can cause life-threatening embolic events. Associated constitutional symptoms may mimic those of inflammatory or connective tissue disorders. Timely diagnosis is of utmost importance because it offers a scope for definitive treatment, i.e. surgical excision. Cardiac myxoma is a relatively rare diagnosis, so physicians should have appropriate preparedness to deal with this entity. This review article has summarised the available information, offered practical tips and highlighted the recent advances.

Citation: Islam AKMM. Cardiac myxomas: A narrative review. World J Cardiol 2022; 14(4): 206-219
URL: https://www.wjgnet.com/1949-8462/full/v14/i4/206.htm
DOI: https://dx.doi.org/10.4330/wjc.v14.i4.206

INTRODUCTION
Cardiac myxomas are primary neoplasms of the heart. Despite a preference for the left atrium, it can involve any of the cardiac chambers. The unusual feature of cardiac myxoma is that it has the biological potential to embolise and grow at the site of embolization[1], causing organ infarction. Timely diagnosis and treatment are essential for the prevention of sometimes life-threatening complications. Though a well-known entity, some aspects of cardiac myxoma are still evolving.

Epidemiology
Cardiac myxoma is a rare disease; however, the exact prevalence is unknown. The reported prevalence is 0.03% in the general population[2]. Annual incidence of cardiac myxoma may be 0.5 to 1 case per million individuals[3,4]. A recently published Spanish study revealed a higher incidence; age-adjusted incidence was 1.6 per million population adjusting to the world population as a reference and 2.1 per million adjusting to the European population[5]. Myxomas are the commonest primary cardiac tumour constituting 50% to 85% of benign ones[6-8]. Middle-aged persons are commonly affected, but no age is immune. The tumour has a female preponderance with a female-to-male ratio of approximately 3:1[3,4]. Two epidemiological forms of cardiac myxoma exist: sporadic and familial. The former is far more common than the latter, constituting about 95% of cases[6].

Anatomy
Cardiac myxomas can affect any chamber of the heart, but the left atrium is most commonly affected. Sites affected include the following: left atrium (75%); right atrium (15%-20%); left ventricle (3%-4%); and right ventricle (3%-4%)[9-12]. Regarding origin, myxoma has a predilection for limbus fossa ovalis of the interatrial septum. However, it can arise from the posterior atrial wall, anterior atrial wall and atrial appendage (Figure 1). The sporadic myxomas are usually single and bear these characteristics. On the other hand, familial myxomas may be multiple, multicentric and arising from atypical sites[13]. Less commonly, myxomas may be bi-atrial or multi-chamber; the latter may be part of the Carney complex[14-18] (Figures 2 and 3). Only rarely, myxomas affect the heart valves[7,19-21].

Myxomas may be ‘more solid’ polypoid in approximately two-thirds of cases or ‘softer’ papillary in one-third of cases[22] (Figure 4). The polypoid myxomas are generally pedunculated, more compact and have less tendency to undergo fragmentation and consequent embolisation[6]. On the other hand, papillary or villous myxomas are gelatinous, less compact, fragile and have a high potential for spontaneous fragmentation and embolisation to the central nervous system, kidney, spleen, extremities and coronary vessels (Figure 5).

Myxomas are considered biologically benign but “functionally malignant” tumours. They usually remain localised to the site of origin. They have a well-documented potential for fragmentation and embolisation. Besides this, metastasis to different locations, including the brain, sternum, spine and pelvis, has been described[23-29].

Myxomas may be enormous, occupying significant parts of the concerned cavity, sometimes termed “giant myxoma” (Figure 6). Rarely, they undergo calcification or osseous metaplasia[30-32] (Figure 7). Occasionally, they get infected[33-35] (Figure 8).

Histology
Histologically cardiac myxomas are mainly composed of stellated fusiform and polygonal cells immersed in an amorphous myxoid stroma[36] (Figure 9). Multinucleated cells are also observed. The cells are shaped and structured in chained rings or nests around the capillaries[37]. The surface of the tumour is often layered by flattened endothelium, while the tumour mass is infused liberally by thin-walled vessels lacking pericytes.
Immunohistochemically, a wide array of biological molecules has been found to be related to the cardiac myxomas, including CD31, CD34, CD56, FVIIIAg, S-100 protein, calretinin, vimentin, desmin, smooth muscle myosin, α1 antitrypsin and alpha 1-antichymotrypsin\cite{38}.

The histogenesis of myxoma is poorly understood; however, the current opinion favours origin from primitive pluripotent mesenchymal cells. Genes encoding heart precursor markers may get reactivated and expressed in cardiac myxoma cells leading to differentiation along endothelial/endocardial lines \cite{39}. Previously, myxomas were thought to arise from Prichard structures, the microscopic endocardial/endothelial structures lined by plump endothelial cells, located in the fossa ovalis\cite{40,41}. Origin from neuroendocrine tissue was also proposed.
Clinical presentation

The clinical presentation of cardiac myxoma depends on their location, size and mobility and is typified by the triad of intracardiac obstruction, embolisation and constitutional symptoms[6]. In a French series of 112 cases of cardiac myxoma, intracardiac obstruction in the form of mitral valve obstruction was the commonest manifestation (67%), followed by embolisation (29%) and constitutional symptoms (34%) [22].

Intracardiac obstruction: Intracardiac obstruction is common in polypoid myxoma. Because of preferential location, mitral valve pseudo-obstruction is the typical presentation[42-48]. Pulmonary hypertension may be present[43,47]. Valvular obstruction may even lead to syncope[46,49]. Right atrial myxomas may obstruct the tricuspid valve, the manifestation of which may be heart failure[50,51] or even collapse[52].
Figure 7 Calcified myxoma in the left atrium. Transesophageal echocardiography shows a large calcified myxoma occupying the left atrial cavity.

Figure 8 Infected myxoma in the left atrium. Transthoracic echocardiography shows a large left atrial myxoma protruding into the left ventricular cavity across the mitral valve. A vegetation with independent mobility is attached to the tumour. The patient presented with prolonged fever with positive blood culture.

Figure 9 Histopathology of myxoma. Histopathological examination shows abundant loose myxoid stroma with scattered round, polygonal or stellate cells with dense irregular nuclei.

**Embolisation:** Embolisation is typically a feature of papillary-type myxomas because of their loose consistency and fragility. Overall, embolism occurs in 30% to 40% of patients with myxomas\[^6\]. The site of embolisation depends on the location of the tumours. Left atrial myxomas commonly embolise to the brain, causing ischaemic stroke and occasionally visual loss. Coronary, renal and limb arteries may also be affected. In a retrospective study of 162 patients with cardiac myxomas surgically treated between 1998 and 2014 in China, the embolic event was observed in 33 patients (20.4%), in the brain (15.43%), limb (3.70%), pulmonary (0.62%) and coronary (0.62%)\[^53\]. Tumour location (atypical), macroscopic
appearance (irregular surface), mean platelet volume and high platelet count were strong risk factors for embolic events in patients with cardiac myxomas in this study. Cerebral embolisation is relatively common, leading to ischaemic stroke\textsuperscript{[54,55]} and cerebral aneurysm formation\textsuperscript{[56]}. Retinal artery occlusion and consequent visual loss have also been reported\textsuperscript{[57-60]}. Coronary embolisation is a rare but well-documented and potentially fatal complication of cardiac myxomas\textsuperscript{[61-64]}. Systemic embolisation may affect multiple sites, e.g., coronaries, viscera and limbs\textsuperscript{[65-67]}. Right-sided myxomas are less prone to embolisation. However, right atrial myxoma, when present, may cause a pulmonary embolism\textsuperscript{[68-73]}. Cardiac myxomas may even embolise peroperatively, leading to complications. Right atrial myxoma was reported to embolise during surgical excision, causing pulmonary embolism and cardiogenic shock and subsequent recovery after removal of the tumour embolus from the pulmonary artery\textsuperscript{[74]}. Constitutional symptoms: Cardiac myxomas are commonly associated with constitutional symptoms mimicking inflammatory or connective tissue disorders\textsuperscript{[75-77]}. These symptoms are more common in women than in men, in right-sided myxomas than in left-sided ones and in large and multcentric myxomas\textsuperscript{[78]}. Malaise, anorexia, fever, arthralgia and weight loss are common. The underlying pathophysiology may be releasing cytokines from the tumour, especially interleukin-6 (IL-6)\textsuperscript{[79]}. In fact, IL-6 may be a more sensitive biomarker than C-reactive protein in predicting the inflammatory status of patients with cardiac myxomas. Sessile, irregular and voluminous tumours tend to be associated with higher circulating IL-6 levels\textsuperscript{[80]}. Myxomas occasionally present with pyrexia of unknown origin\textsuperscript{[79,81]}. They may mimic bronchial asthma\textsuperscript{[82]} or pulmonary tuberculosis\textsuperscript{[14]}. Rarely, myxomas are associated with pleural effusion\textsuperscript{[14,83,84]}. Infected myxoma: Occasionally, myxomas get infected, presenting with high fever and multiple embolic events\textsuperscript{[85-88]} \textsuperscript{[Figure 8]}. Cardiac myxoma in pregnancy: Occasionally, cardiac myxomas are diagnosed for the first time in pregnancy, mostly by echocardiography. Favourable maternal and foeto-neonatal outcomes with surgical management of cardiac myxoma in the pregnant patients have been reported in a recent review of 44 articles with 51 patients\textsuperscript{[89]}. PHYSICAL EXAMINATION Cardiac myxomas are typified by the triad of intracardiac obstruction, embolic manifestations and constitutional symptoms. However, because of heterogeneity in location, size, morphology and histopathology, they may remain entirely asymptomatic, present with classical manifestations or produce life-threatening emergency of systemic embolisation or even sudden cardiac death\textsuperscript{[90]}. As little as 10\% to as high as 50\% of the myxomas may be diagnosed incidentally during clinical evaluation\textsuperscript{[91,92]}. General examination may reveal cachexia, fever, cyanosis, clubbing or rash. Neck veins may be engorged, and there may be a prominent A wave in the jugular venous pulse. Precordial findings may mimic mitral stenosis. The first heart sound (S1) may be loud and widely split because of the delay in the closure of the mitral valve due to the prolapse of the tumour into the mitral valve orifice. The pulmonary component of the second heart sound (P2) may be normal or loud depending on the presence of pulmonary hypertension. The characteristic “tumour plop” is a low-pitched early diastolic sound just after the S2. It may be confused with the opening snap of rheumatic mitral stenosis; however, the latter is high-pitched. It may be followed by a low-pitched diastolic murmur. The tumour plop is produced by the impact of the myxoma against the endocardial wall or when its excursion is halted. Also, a third heart sound (S3), fourth heart sound (S4) or a diastolic murmur of functional mitral or tricuspid stenosis may be audible. Occasionally, a systolic murmur of mitral or tricuspid regurgitation may be present. The auscultatory findings of cardiac myxomas characteristically change with changes in the position of the patient. INVESTIGATIONS Echocardiography is the critical investigation for the diagnosis of cardiac myxomas. Other imaging modalities like computed tomography (CT) scanning and magnetic resonance imaging play an ancillary role. Chest X-ray and electrocardiography are of limited value. Haematological investigations are also routinely done. Histopathology confirms the diagnosis. Genetic testing plays a vital role in familial cases of myxomas. Echocardiography Transthoracic echocardiography is the most practical investigation and often yields adequate information necessary for surgical resection. It makes the diagnosis and determines the location, size
and shape of the tumour and its connections. Transesophageal echocardiography has a higher sensitivity and specificity and can detect small tumours, tumours located at atypical locations and possible multichamber myxomas[93-97].

Three-dimensional transthoracic echocardiography and transoesophageal echocardiography have also been used[98]. In a European study, transoesophageal echocardiography was superior to transthoracic echocardiography for myxoma detection (100% vs 95%) and attachment point identification (95.2% vs 64.5%)[99].

The classical features of an atrial myxoma in echocardiography include polypoid or papillary mass attached to the interatrial septum through a stalk and moving to and fro into the cavity, sometimes protruding into the corresponding ventricular cavity across the atrioventricular valve (Figure 10). Occasionally, the tumour mass may get areas of liquefaction or calcification. Doppler echocardiography shows the hemodynamic consequences of atrial myxoma.

During echocardiography, differentiation between myxoma and thrombus is of crucial importance. Myxomas typically have a stalk, a preference for limbus fossa ovalis of the atrial septum for stalk attachment and characteristic mobility. On the other hand, the thrombus is usually situated in the posterior portion of the atrium, has a preference for the atrial appendage, has a layered appearance and is most commonly seen in the presence of valvular mitral stenosis, atrial fibrillation and spontaneous echo contrast.

Contrast echocardiography can aid in the differential diagnosis of intracardiac masses based on perfusion of the mass. Malignant tumours are frequently highly vascular and present greater contrast enhancement than the adjacent myocardium, whereas myxomas demonstrate partial perfusion with lesser contrast enhancement than the adjoining myocardium. Thrombi, being avascular, show a complete absence of perfusion[100-102].

Despite the invaluable role of echocardiography and other imaging modalities, histopathological examination is the gold standard test for confirmation of the diagnosis of cardiac myxomas. A recently published study from Korea shows that out of 265 cases with an echocardiographic diagnosis of cardiac myxomas, 174 (65.7%) were surgically confirmed as myxomas. Compared with cardiac myxomas, other tumours were smaller and more frequently found in non-atrial sites[103].

**ECG**

ECG findings are nonspecific. Atrial enlargement or ventricular hypertrophy may be present. In contrast to the findings in mitral valve disease, atrial fibrillation is uncommon[6].

**Other imaging modalities**

Chest skiagram has a limited role. Occasionally, it can present features of mitral stenosis, e.g., straightening of the left cardiac border and double contour of the right cardiac border and only rarely tumour calcification. Signs of pulmonary hypertension may be present.

Magnetic resonance imaging provides helpful information about the myxoma size, shape, surface characteristics and even its mobility on cine magnetic resonance gradient echo. The most frequent presentation is a mass isointense at T1-weighted and hyperintense at T2-weighted imaging with foci of hypointensity at one or two of these sequences[104]. Also, tissue characteristics can be used to differentiate a tumour from a thrombus.

CT scanning, generally, is not useful for the diagnosis of cardiac myxomas because it cannot reliably differentiate between myxomas and thrombi[105]. Typically, myxomas appear homogenous and isodense or as a slightly hypodense mass on non-contrast CT scanning, which does not show enhancement after iodinated contrast injection[106]. However, CT is the preferred technique to detect calcification, which is encountered in 10%–30% of cases[106,107].
Fluorodeoxyglucose positron emission tomography scanning is not typically indicated in the evaluation for myxoma[108].

**Angiocardiography**

Angiocardiography is seldom used for diagnosis of cardiac myxomas because of availability of non-invasive investigation modalities especially echocardiography. Also, manipulation of a catheter during angiocardiography carries a high risk of embolisation of tumour fragments[109,110]. In angiocardiography, cardiac myxomas typically appear as filling defects. In cases of left atrial myxoma, the levophase of a pulmonary angiogram may outline a radiolucent mass within the left atrium.

**Genetic testing**

Genetic testing for mutations in the **PRKAR1A** gene is increasingly used for diagnostic certainty of Carney complex.

**Haematological tests**

Erythrocyte sedimentation rate and C-reactive protein are generally elevated. Anaemia may be present. IL-6 rises especially when constitutional symptoms dominate.

---

### TREATMENT

Cardiac myxoma needs surgical excision often on an emergency basis. This is to reduce the risk of embolisation of the tumour. Surgery is otherwise simple. The root of the stalk and the full thickness of the adjacent interatrial septum is excised, and the consequent atrial septal defect is closed accordingly. Data published over the past decades show excellent overall outcomes in operative mortality, short- and long-term survival and tumour recurrence[4,101-118]. Surgical excision of 23 myxomas in Turkey between 2010 and 2017 showed excellent outcomes with no early or late mortality[112]. A 16-year single centre study from China reported no need for secondary surgery in 97.4% ± 2.5% of cases after 10 years. Overall, the actuarial survival was 98.4% ± 1.6% at 5 years and 96.0% ± 2.8% at 10 years[113].

A similar encouraging outcome was observed in Italy; surgical excision of 98 cardiac myxomas between 1990 and 2007 showed 3% operative mortality. Actuarial survival was 98%, 98% and 89% at 5, 10 and 15 years, respectively. There was only one recurrence 68 mo after the first surgery[115].

In a smaller series of 18 patients treated surgically over 5 years in the United Kingdom, no death occurred within 30 d post-procedure[116]. Follow-up of surgical treatment of cardiac myxomas in Germany showed no in-hospital deaths. Out of 57 patients, 52 were alive at a median follow-up of 7.5 years[117]. Between 2002 and 2008, 34 cardiac myxomas were operated on in a single centre in Pakistan; 32 patients survived the surgery, 2 patients died over a median follow-up of 34 mo, and 1 patient had recurrence after 27 mo[118]. Twenty-four years of experience in 49 patients from Austria revealed relatively low early mortality of 2.0% and late mortality of 6.1%. The long-term prognosis was excellent, with an actuarial survival rate of 0.74. The rate of reoperations was low, with 2.0% after 24 years[4]. In a recently published small study from Bangladesh, all 20 patients with cardiac myxoma survived the surgery, and 1 patient presented with recurrence 28 mo after the surgery[111]. In recent years, cardiac myxomas have been excised successfully by minimally invasive surgery with or without robotic assistance[119-122]. Robotic surgery has been associated with early restoration of normal quality of life and early return to employment[121].

Utmost caution is warranted during surgical excision of cardiac myxomas because of their potential for embolisation peroperatively[74].

---

### FAMILIAL CARDIAC MYXOMAS

Familial cardiac myxoma is rare and tend to form a syndrome, e.g., Carney complex. They can usually be distinguished from the sporadic forms by the presentation at a younger age, the unusual location and multicentricity of the lesions and the presence of rare pathological conditions. In addition, a higher rate of recurrent lesions is usually associated with the familial forms of this disease. Carney complex is a rare multiple neoplasia syndrome, characterised by pigmented lesions of the skin and mucosa, cardiac and extra-cardiac myxomatous tumours and multiple endocrine and non-endocrine neoplasms (Figure 3)[123,124]. It is inherited as an autosomal-dominant disorder in three-fourths of the cases. In the remaining one-fourth, it occurs sporadically as a result of a de novo genetic mutation[125]. The disease is caused by inactivating mutations or large deletions of the **PRKAR1A** gene located at 17q22-24 coding for the regulatory subunit I alpha of protein kinase A (PKA) gene[126]. Myxomatous tumours also occur in the skin and breast. Lentigines, blue nevus and cutaneous myxoma are the common skin manifestations (Figure 3). Primary pigmented nodular adrenocortical disease and thyroid nodules are examples of endocrinopathies[127,128].
Table 1 Diagnostic criteria for Carney complex

| Diagnostic criteria |
|---------------------|
| Spotty skin pigmentation with a typical distribution (lips, conjunctiva and inner or outer canthi, vaginal and penile mucosa) |
| Myxoma (cutaneous and mucosal) |
| Cardiac myxoma |
| Breast myxomatosis or fat-suppressed magnetic resonance imaging findings suggestive of this diagnosis |
| Primary pigmented nodular adrenocortical disease or paradoxical positive response of urinary glucocorticosteroids to dexamethasone administration during Liddle’s test |
| Acromegaly due to growth hormone-producing adenoma |
| Large cell calcifying Sertoli cell tumour or characteristic calcification on testicular ultrasonography |
| Thyroid carcinoma or multiple, hypoechoic nodules on thyroid ultrasonography, in a young patient |
| Psammomatous melanotic schwannoma |
| Blue nevus, epithelioid blue nevus (multiple) |
| Breast ductal adenoma (multiple) |
| Osteochondromyxoma |

Supplemental criteria:

- Affected first-degree relative
- Inactivating mutation of the PRKAR1A gene

With histologic confirmation.

The Carney complex is diagnosed by the diagnostic criteria defined by Stratakis et al[124] (Table 1). Making the diagnosis, required either: (1) Two of the twelve manifestations of the disease listed; or (2) One of the twelve manifestations and one of the supplemental criteria. Genetic testing for mutations in the PRKAR1A gene confirms the diagnosis. For management, cardiac myxoma needs surgical excision. Primary pigmented nodular adrenocortical disease and pituitary adenomas are managed surgically, or the latter can be managed with somatostatin analogues[129,130]. Prognosis is good at present; however, lifelong follow-up is indicated[126].

CONCLUSION

Cardiac myxomas are the commonest neoplasm of the heart. They are primarily sporadic but may be familial as Carney complex. Though histologically benign, myxomas are prone to cause intracardiac obstruction and embolisation. Associated constitutional features may mimic inflammatory and connective tissue disorders creating diagnostic dilemmas. Echocardiography is a versatile tool for making the diagnosis and choosing the optimum management strategy. Surgery is the mainstay of treatment with an excellent prognosis. Long-term follow-up is often needed to look for recurrence. Physicians should have appropriate preparedness to diagnose this uncommon entity. Only timely diagnosis and prompt surgery can reduce the morbidity and mortality of cardiac myxoma patients.

FOOTNOTES

Author contributions: Islam AKMM conceptualized the review and wrote and approved the manuscript.

Conflict-of-interest statement: All authors declare having no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Bangladesh
REFERENCES

1. Velez Torres JM, Martinez Duarte E, Diaz-Perez JA, Rosenberg AE. Cardiac Myxoma: Review and Update of Contemporary Immunohistochemical Markers and Molecular Pathology. Adv Anat Pathol 2020; 27: 380-384 [PMID: 32732585 DOI: 10.1097/PAP.0000000000000275]

2. Grebenc ML, Rosado de Christenson ML, Burke AP, Green CE, Galvin JR. Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation. Radiographics 2000; 20: 1073-103; quiz 1110 [PMID: 1090697 DOI: 10.1148/radiographics.20.4.g00j081073]

3. Yoon DH, Roberts W. Sex distribution in cardiac myomas. Am J Cardiol 2002; 90: 563-565 [PMID: 12208428 DOI: 10.1016/s0002-9149(02)02540-7]

4. Keeling IM, Oberwalder P, Anelli-Monti M, Schuchlenz H, Demel U, Tilz GP, Rehak P, Rigler B. Cardiac myxomas: 24 years of experience in 49 patients. Eur J Cardiothorac Surg 2002; 22: 971-977 [PMID: 12467822 DOI: 10.1016/s0905-9283(01)00379-2]

5. Pérez-Andreu J, Arribas Leal JM, Gervase G, Rivera-Caravaca JM, Cánovas López S, Marin F. Epidemiology of Cardiac Myxoma in a Spanish Population. A 30-year Surgical Series. Rev Esp Cardiol (Engl Ed) 2019; 72: 685-686 [PMID: 30316735 DOI: 10.1016/j.rec.2018.08.021]

6. Reynen K. Cardiac myxomas. N Engl J Med 1995; 333: 1610-1617 [PMID: 7477198 DOI: 10.1056/NEJM199512143332407]

7. Wold LE, Lie JT. Cardiac myxomas: a clinicopathologic profile. Am J Pathol 1980; 101: 219-240 [PMID: 7446701 DOI: 10.1016/0002-8703(80)90019-9]

8. GOLDBERG HP, GLENN F, DOTTER CT, STEINBERG I. Myxoma of the left atrium; diagnosis made during life with operative and post-mortem findings. Circulation 1952; 6: 762-767 [PMID: 1298355 DOI: 10.1161/01.cir.6.5.762]

9. Hall RJ, Cooley DA, McAllister HA Jr, Frazier OH. Neoplastic heart disease. In: Hurst JW, ed. The heart, arteries and veins. 7th ed. New York: McGraw-Hill, 1990:1382-403

10. Silverman NA. Primary cardiac tumors. Ann Surg 1980; 191: 127-138 [PMID: 7362282 DOI: 10.1097/00000565-198002000-00001]

11. McAllister HA, Fenoglio JJ. Tumors of the cardiovascular system. Atlas of tumor pathology. 2nd Series. Fascicle 15. Washington, DC: Armed Forces Institute of Pathology, 1978:1-20

12. Meller J, Teichholz LE, Pichard AD, Matta R, Litwak R, Herman MV, Massie KF. Left ventricular myxoma: echocardiographic diagnosis and review of the literature. Am J Med 1977; 63: 816-823 [PMID: 939052 DOI: 10.1016/0002-9343(77)90168-1]

13. McCarthy PM, Piehler JM, Schaff HV, Pluth JR, Orszulak TA, Vidaillert HJ Jr, Carney JA. The significance of multiple, recurrent, and “complex” cardiac myxomas. J Thorac Cardiovasc Surg 1986; 91: 389-396 [PMID: 3951243 DOI: 10.1016/s0022-2552(86)80415-1]

14. Islam AKMM, Islam KS, Ananya KF, Uddin MJ. A Tuberculosis Case Is Discovered to Be Carney Complex Instead! CASE (Phila) 2020; 4: 369-373 [PMID: 33117931 DOI: 10.1016/j.case.2020.05.010]

15. Islam AM, Rahman MT, Paul TK. Biatrial myxoma in a young male patient. Korean Circ J 2011; 41: 770-771 [PMID: 22259612 DOI: 10.4070/kcj.2011.41.12.770]

16. Dittmann H, Voelker W, Karsch KR, Seipel L. Bilateral atrial myxomas detected by transesophageal two-dimensional echocardiography. Am Heart J 1989; 118: 172-173 [PMID: 2747814 DOI: 10.1016/0002-8541(89)90088-4]

17. Tway KP, Shah AA, Rahimtoola SH. Multiple bilateral myxomas demonstrated by two-dimensional echocardiography. Am J Med 1981; 71: 896-899 [PMID: 304662 DOI: 10.1016/0002-9343(81)90394-4]

18. Balk AH, Wagenaar SS, Bruscheke AV. Bilateral cardiac myxomas and peripheral myxomas in a patient with recent myocardial infarction. Am J Cardiol 1979; 44: 767-770 [PMID: 484504 DOI: 10.1016/0002-9149(79)90300-x]

19. Sharma SC, Kulkarni A, Bhargava V, Modak A, Lashkare DV. Myxoma of tricuspid valve. J Thorac Cardiovasc Surg 1990; 99: 1985-1986 [PMID: 2023453]

20. Blondeau P. Primary cardiac tumors—French studies of 533 cases. Thorac Cardiovasc Surg 1990; 38 Suppl 2: 192-195 [PMID: 72239701 DOI: 10.1055/s-2007-1014065]

21. Sandrasagra FA, Oliver WA, English TA. Myxoma of the mitral valve. Br Heart J 1979; 42: 221-223 [PMID: 486284 DOI: 10.1136/hrt.42.2.221]

22. Pinede L, Duhat P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. Medicine (Baltimore) 2001; 80: 159-172 [PMID: 11388092 DOI: 10.1097/00005792-200105000-00002]

23. Wan Y, Du H, Zhang L, Guo S, Xu I, Li Y, He H, Zhou L, Chen Y, Mao L, Jin H, Hu B. Multiple cerebral metastases and metastatic aneurysms in patients with left atrial Myxoma: a case report. BMC Neurol 2019; 19: 249 [PMID: 31646971 DOI: 10.1186/s12883-019-1474-4]

24. Brinjikji W, Morris JM, Brown RD, Thienel KR, Wald JT, Giannini C, Cloft HJ, Wood CP. Neuroimaging Findings in Cardiac Myxoma Patients: A Single-Center Case Series of 47 Patients. Cerebrovasc Dis 2015; 30: 35-44 [PMID: 26066450 DOI: 10.1159/000381833]

25. Zhan R, Ji T, Fan Z, Pan D. Perplexing imaging manifestations of multiple metastatic intracranial lesions associated with atrial myxoma. J Craniofac Surg 2013; 24: 651-652 [PMID: 23524767 DOI: 10.1097/SCS.0b013e318264690f]
Ihsen Z. Retrospective analysis.

Alamri Y. Manifestation.

Agstam S. Atrial myxoma causing syncope in a middle-aged man.

Rajani AR. Obstruction: diagnosis by computed tomography.

Thangaroopan M. Large left atrial myxoma.

Theodoropoulos KC. Brain metastasis of cardiac myxoma: case report and review of the literature.

Altundag K. Brain metastasis of cardiac myxoma: case report and literature review.

Altundag MB. Metastatic atrial myxoma to the temporal bone: case report.
Clinical and Practical Considerations.

Strâmbu I, Cakar MA. Asthma. Cardiovasc Surg 2010; 18: 495-498

Lin JN. A Case of Infected Left Atrial Myxoma Presenting as ST-Elevation Myocardial Infarction (STEMI). Am J Case Rep 2020; 21: 1856-1858

Endo A, young woman. Left Atrial Myxoma While Characterising an Autoimmune Disease. Eur Heart J Case Rep 2020; 4: 177

Lazaros G, Moreno-Ariño M. Left Atrial Myxoma: A case report and review of the literature. Card Surg 2015; 30: 776-783

Papadopoulos K, Pandey AC, 10.1097/MD.0000000000018386

Yu Y, Zhu Y, Dong A, Su Z. Retinal artery occlusion as the manifestation of left atrial myxoma: a case report. BMC Ophthalmol 2014; 14: 164

Peeters H, Lepor H, Lai CH, Lu LF, Lin HH. Fever of unknown origin from a left atrial myxoma: an immunologic basis and cytokine profile. J Intern Med 2005; 258: 20-27

Wu Y, Huang P, Li J, et al. Cytokine expression in cardiac myxoma: A case report and review of the literature. Medicine (Baltimore) 2018; 97: e11653

Marta L, Peres M, Alves M, Ferreira da Silva G. Giant left atrial myxoma presenting as acute myocardial infarction. Rev Port Cardiol 2012; 21: 815-819

Braun S, Schröter H, Reynek K, Schwencke C, Strasser RH. Myocardial infarction as complication of left atrial myxoma. Int J Cardiol 2005; 101: 115-121

Latifi AN, Ibe U, Gnanaraj J. A case report of atrial myxoma presenting with systemic embolization and myocardial infarction. Eur Heart J Case Rep 2019; 3: yzt104

Wu Y, Fu XM, Liao XB, Zhou X. Stroke and peripheral embolisms in a pediatric patient with giant atrial myxoma: Case report and review of current literature. Medicine (Baltimore) 2018; 97: e11653

Bernatchez J, Gaudreault V, Vincent G, Rheaume P. Left Atrial Myxoma Presenting as an Embolic Wobble: A Case Report and Review of Literature. Ann Vasc Surg 2018; 53: 266.e13-266.e20

Ma G, Wang D, He Y, Zhang R, Zhou Y, Ying K. Pulmonary embolism as the initial manifestation of right atrial myxoma: A case report and review of the literature. Medicine (Baltimore) 2019; 88: e18386

Pandey AC, Carey JH, Thompson JL. Right atrial myxoma presenting as a pulmonary embolism in a 32-year-old female. JRSM Cardiovasc Dis 2019; 8: 204800418187660

Kurnicka K, Domienik-Karłowicz J, Ciurzyński M, Biederman A, Pruszczyk P. Right atrial myxoma with pulmonary embolism. Kardiol Pol 2015; 73: 298

Aydin C, Taşal A, Ay Y, Vatan-Kulcu MA, Inan B, Bacaksız A. A giant right atrial villous myxoma with simultaneous pulmonary embolism. Int J Card Surg Case Rep 2015; 4: 206-208

Subhan V, Lakshmanan A, Sethurathinam R, Ajit MS. Right atrial myxoma—an unusual cause of pulmonary embolism. J Card Surg 2012; 27: 604

Cheema U, Thomas J. A giant right atrial myxoma presenting as acute pulmonary embolism. Eur Heart J Cardiovasc Imaging 2012; 13: 799

Papadopoulos K, Alexiou C, Ozden Tok O, Vannan MA. Intraoperative embolism of a right atrial myxoma: a case report. Eur J Cardiothorac Surg 2020; 57: 1-4

Garcia-Carretero R, Naranjo-Mansilla G, Luna-Heredia A, Arias-Baldo P, Beamonte-Vela BN. Incidental Finding of a Large Left Atrial Myxoma: A Case Report. J Crit Care Med (Targu Mures) 2018; 3: 30810670

Lazaros G, Masourea C, Brili S, Stavropoulou G, Kafi A, Stefanadis C. Large left atrial myxoma in an oligosymptomatic young woman. Hellenic J Cardiol 2013; 54: 60-63

Endo A, Ohtahara K, Kinugawa T, Ogino K, Hisatome I, Shigemasa C. Characteristics of cardiac myxomas with constitutional signs: a multicenter study in Japan. Clin Cardiovasc Med 2002; 25: 367-370

Yuan SM, Lin HZ. Predictors of Normalization of Circulating Interleukin-6 after Cardiac Myxoma Resection. Braz J Cardiovasc Surg 2019; 34: 22-27

Lin JN, Lai CH, Lin HH. Fever of unknown origin from a left atrial myxoma: an immunologic basis and cytokine association. South Med J 2011; 104: 360-362

Zuvas L, Quarrie R, Allen E, Haas C. Severe functional mitral stenosis due to a left atrial myxoma masquerading as asthma. BMJ Case Rep 2018; DOI: 10.1136/bcr-2018-236876

Cakar MA, Arslan C, Yildiz A, Vatan MB, Gunduz H. Left atrial myxoma with pleural effusion. J Clin Med Res 2009; 1: 297-299

Strâmbu I, Ilijeu A, Cretul R, Stoicescu IP. [Recent pleural effusion revealing a left atrial myxoma]. Pneumologie 2002; 51: 54-58

Valta K, Ozzurc K, Valta T, Yrjkin E. Systemic Inflammation in the Setting of Cardiac Myxomas: an Overview of Clinical and Practical Considerations. Korean Circ J 2021; 51: 784-786
Islam AKMM. Cardiac myxomas

WJC 2021; 30: 386-394 [PMID: 26313731 DOI: 10.9535/1678-9741.20150012]

Rio RE, Burmeister DB, Bean EW. Complications of atrial myxoma. Am J Emerg Med 2016; 34: 2465.e1-2465.e2 [PMID: 27324853 DOI: 10.1016/j.ajem.2016.05.079]

Goev I, Paic F, Durić Z, Gotev M, Ivčević S, Jakšić FB, Bićočić B. Cardiac myxoma the great imitators: comprehensive histopathological and molecular approach. Int J Cardiol 2013; 164: 7-20 [PMID: 22243936 DOI: 10.1016/j.ijcard.2011.12.052]

Beghetti M, Gow RM, Haney I, Mawson W, Freedom RM. Pediatric primary benign cardiac tumors: a 15-year review. Am Heart J 1997; 134: 1107-1114 [PMID: 9424072 DOI: 10.1016/s0002-9739(97)0032-2]

Obeid AI, Marvasti M, Parker F, Rosenberg J. Comparison of transthoracic and transesophageal echocardiographic in diagnosis of left atrial myxoma. Am J Cardiol 1989; 63: 1006-1008 [PMID: 2929455 DOI: 10.1016/0002-9149(89)90162-8]

Gardinglajkar S, Reedhar R. Intraoperative evaluation of left atrial myxoma using real-time 3D transesophageal echocardiography. Ann Card Anaesth 2010; 13: 180-181 [PMID: 20442555 DOI: 10.4103/0971-9784.62937]

Gardinglajkar S, Reedhar R. Utility of transesophageal echocardiography during surgery on left atrial myxoma. Ann Card Anaesth 2009; 11: 142-143 [PMID: 18603756 DOI: 10.4103/0971-9784.41159]

Srêvastava R, Hsing MC, Fadel A, Nanda NC. Transesophageal echocardiographic demonstration of bialtral myxoma. Echocardiography 2004; 21: 187-188 [PMID: 14961801 DOI: 10.1111/j.0742-2822.2004.03090.x]

Pérez de Isla L, de Castro R, Zamorano JL, Almería C, Moreno R, Moreno M, Lima P, García Fernández MA. Diagnosis and treatment of cardiac myxomas by transesophageal echocardiography. Am J Cardiol 2002; 90: 1419-1421 [PMID: 12480063 DOI: 10.1016/s0002-9149(02)02891-6]

Tolstrup K, Shiota T, Gurudevan S, Lutherhing L, Luo H, Siegel RJ. Left atrial myxomas: correlation of two-dimensional and live three-dimensional transesophageal echocardiography with the clinical and pathological findings. J Am Soc Echocardiogr 2011; 24: 618-624 [PMID: 21367575 DOI: 10.1016/j.echo.2011.01.007]

Engberding R, Daniel WG, Erbel R, Kasper W, Lestuzzi C, Curtius JM, Sutherland GR, Lambertz H, von Hehn A, Lesbre JP. Diagnosis of heart tumours and thrombi: a multicentre study in 154 patients. European Cooperative Study Group. Eur Heart J 1993; 14: 1223-1228 [PMID: 8223737 DOI: 10.1093/euheart/14.9.1223]

Bhattacharyya S, Khattar R, Senior R. Characterisation of intra-cardiac masses by myocardial contrast echocardiography. J Int Cardiol 2016; 163: e11-e13 [PMID: 22805540 DOI: 10.1016/j.jicard.2012.06.098]

Uenishi EK, Caldas MA, Saroute AN, Tsutsui JM, Piotto GH, Falcão SN, Mathias W Jr. Contrast echocardiography for the evaluation of tumors and thrombi. Arq Bras Cardiol 2008; 91: e48-e52 [PMID: 19142370 DOI: 10.1590/s0002-9149.2008000100015]

Kirkpatrick JN, Wong T, Bednarz JE, Spencer KT, Sugeng L, Ward RP, DeCara JM, Weinert L, Krauss T, Lang RM. Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging. J Am Coll Cardiol 2004; 43: 1412-1419 [PMID: 15093876 DOI: 10.1016/j.jacc.2003.09.065]

Lee SH, Park JS, Park JH, Chin JY, Yoon WS, Kim HY, Cho JY, Kim KH, Kim WH. Comparison of Clinical and Echocardiographic Characteristics between Cardiac Myxomas and Masses Mimicking Myxoma. Korean Circ J 2020; 50: 822-832 [PMID: 32725996 DOI: 10.4070/kcj.2020.0024]

Colin GC, Dymarkowski S, Gerber B, Michoux N, Bogaert J. Cardiac myxoma imaging features and tissue characteristics at cardiovascular magnetic resonance. Int J Cardiol 2016; 202: 950-951 [PMID: 26493410 DOI: 10.1016/j.ijcard.2015.10.011]

Scheffel H, Baumueller S, Stolzmann P, Leschka S, Plass A, Alkadhi H, Schertler T. Atrial myxomas and thrombi: comparison of imaging features on CT. AJR Am J Roentgenol 2009; 192: 639-645 [PMID: 19234259 DOI: 10.2214/AJR.08.1694]

Shin W, Choe YH, Kim SM, Song IY, Kim SS. Detection of cardiac myxomas with non-contrast chest CT. Acta Radiol 2014; 55: 273-278 [PMID: 23926237 DOI: 10.1177/0266479513496561]

Grebe ML, Rosado-de-Christenson ML, Green CE, Burke AP, Galvin JR. Cardiac myxoma: imaging features in 83 patients. Radiographics 2002; 22: 673-689 [PMID: 12006696 DOI: 10.1148/rg.2233.0202673]

Colin GC, Gerber BL, Amuzuluć M, Bogaert J. Cardiac myxoma: a contemporary multimedia imaging review. J Cardiovasc Imaging 2018; 34: 1789-1808 [PMID: 29974293 DOI: 10.1016/j.jcin.2018.03.196]

Wagner WL, Manz M, Steudel A, Kirchhoff PG, Lüdtertz B. [Noninvasive diagnosis of bilarcele left atrial and right ventricular myxoma of the heart]. Z Kardiol 1988; 77: 251-255 [PMID: 3388940]

Pindyck F, Peirce EC 2nd, Baron MG, Lukban SB. Embolization of left atrial myxoma after transseptal cardiac catheterization. Am J Cardiol 1972; 30: 569-571 [PMID: 5073672 DOI: 10.1016/0002-9149(72)90052-5]

Hosain N, Quamium Chowdhury MA, Maruf MF, Chowdhury MR, Baruš S, Rahman M. Surgical Treatment of Atrial Myxomas: Outstanding Outcome of a Treacherous Tumor. CJIC Open 2021; 3: 354-360 [PMID: 33778452 DOI: 10.1016/j.cjico.2020.02.011]

Gür AK, Ayyaç MC. Surgical Treatment of Cardiac Myxomas: A 23-Case Experience. Heart Surg Forum 2018; 21: E370-E374 DOI: 10.1532/hsf.18-000175

Lin Y, Xiao J, Chen J, Hong J, Peng H, Kang B, Wu L, Wang Z. Treating cardiac myxomas: a 16-year Chinese single-center study. J Cardiovasc Med (Hagerstown) 2016; 17: 44-53 [PMID: 24933197 DOI: 10.1016/j.jocm.2010.02.011]
Vroomen M, Houthuizen P, Khamoushian A, Soliman Hamad MA, van Straten AH. Long-term follow-up of 82 patients after surgical excision of atrial myxomas. *Interact Cardiovasc Thorac Surg* 2015; 21: 183–188 [PMID: 25972592 DOI: 10.1093/icvts/ivv125]

Garatti A, Nano G, Canziani A, Gagliardotto P, Mosuoto E, Frigioala A, Menicanti L. Surgical excision of cardiac myxomas: twenty years experience at a single institute. *Ann Thorac Surg* 2012; 93: 825–831 [PMID: 22296980 DOI: 10.1093/athoracsur.2011.11.009]

Owerr CE, Vaughan P, Braidedly PC, Wilkinson GA, Cooper GJ, Hopkinson DN, Sarkar PK. Atrial myxomas: a single unit's experience in the modern era. *Heart Surg Forum* 2011; 14: E105-E109 [PMID: 21521672 DOI: 10.1532/HSF98.20101163]

Kuroczyński W, Peivandi AA, Ewald P, Pruefer D, Heinemann M, Vahl CF. Cardiac myxomas: short- and long-term follow-up. *Cardiol J* 2009; 16: 447-454 [PMID: 19753524]

Garatti A, Nano G, Canziani A, Gagliardotto P, Mosuoto E, Frigioala A, Menicanti L. Surgical excision of cardiac myxomas: twenty years experience at a single institute. *Ann Thorac Surg* 2012; 93: 183-188 [PMID: 22296980 DOI: 10.1093/athoracsur.2011.11.009]

Kuroczyński W, Peivandi AA, Ewald P, Pruefer D, Heinemann M, Vahl CF. Cardiac myxomas: short- and long-term follow-up. *Cardiol J* 2009; 16: 447-454 [PMID: 19753524]

Onan B, Kahraman Z, Erturk M, Erkanli K. Robotic resection of giant left ventricular myxoma causing outflow tract obstruction. *J Card Surg* 2017; 32: 281-284 [PMID: 28417503 DOI: 10.1111/jocs.13128]

Yang M, Yao M, Wang G, Xiao C, Wu Y, Zhang H, Gao C. Comparison of postoperative quality of life for patients who undergo atrial myxoma excision with robotically assisted versus conventional surgery. *J Thorac Cardiovasc Surg* 2015; 150: 152-157 [PMID: 22640373 DOI: 10.1016/j.jtcvs.2015.01.056]

Stratakis CA. Genetics of Carney complex and related familial lentiginoses, and other multiple tumor syndromes. *Front Biosci* 2006; 5: D353-D366 [PMID: 17004431 DOI: 10.2741/stratakis]

Watson JC, Stratagakis CA, Bryant-Greenwood PK, Koch CA, Kirschner LS, Nguyen T, Carney JA, Oldfield EH. Neurosurgical implications of Carney complex. *J Neurosurg* 2009; 92: 413-418 [PMID: 19701527 DOI: 10.3171/jns.2009.92.3.0413]
